Lacidipine: a review of its use in the management of hypertension.

  title={Lacidipine: a review of its use in the management of hypertension.},
  author={Paul L. McCormack and Antona J. Wagstaff},
  volume={63 21},
UNLABELLED Lacidipine (Caldine, Lacimen, Lacipil, Midotens, Motens) is a once-daily, orally-administered, lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity, resulting in a lack of reflex tachycardia. It has a long duration of action and a high degree of vascular selectivity. In addition to calcium channel-modulated vasodilation, lacidipine displays antioxidant activity greater than that of other dihydropyridine calcium antagonists. In randomised, well… 

The Role of Existing and Newer Calcium Channel Blockers in the Treatment of Hypertension

  • J. Basile
  • Medicine, Biology
    Journal of clinical hypertension
  • 2004
Calcium channel blockers, which include both dihydropyridines and non‐dihydropyridine, are among the most widely prescribed agents for the management of essential hypertension and appear less effective than angiotensin‐converting enzyme inhibitors and diuretics for preventing heart failure and myocardial infarction.

Calcium channel blockers in the elderly: current status in the treatment of hypertension

Calcium channel blockers remain less effective than thiazide-type diuretics and angiotensin-converting enzyme inhibitors for preventing heart failure, but are particularly effective for improving outcomes in those with isolated systolic hypertension.

Could Baroreceptor Activation Therapy Be the Future for Treating Hypertension and Other Chronic Cardiovascular Conditions?

  • C. Ram
  • Medicine, Biology
    Journal of clinical hypertension
  • 2010
A novel therapeutic option is becoming available that allows appropriate physiologic adaptation to elevated SNS activation and reduced parasympathetic activation (and thus elevated BP) by electrically stimulating the carotid baroreflex.

Baroreceptor activation therapy for treating resistant hypertension : a status report C

Clinicians are currently left with few therapeutic options that fully address the underlying pathophysiology of this disorder, and may have to choose therapies that lower blood pressure but which may aggravate the pathology of sns hyperactivation.

Candesartan Treatment for Peripheral Occlusive Arterial Disease after Stent Angioplasty

Although not significant, candesartan treatment tended to improve the prognostic benefits after stent implantation, suggesting that an antiproliferative effect after stenting may need higher doses than an antihypertensive effect of the drug.

A meta-analysis of the efficacy and safety of lacidipine in Chinese patients with mild to moderate essential hypertension

Meta-analysis showed that there was a significant difference between the total efficiency and adverse effect of lacidipine and other antihypertensive drugs.

Transdermal delivery of calcium channel blockers for hypertension

This review explores the investigations on the feasibility and applicability of systemic delivery of various CCBs via skin and holds promise for the long-term success in technologically advanced transdermal dosage forms being commercialized sooner rather than later.

Lacidipine attenuates reserpine-induced depression-like behavior and oxido-nitrosative stress in mice

It can be inferred that lacidipine (Ca2+ channel antagonist) attenuates depression-like symptoms in reserpine-treated mice and the abrogation of antidepressant-like effects of LCD by Bay-K8644 revealed that modulation of Ca2-channels might present a potential strategy in the management of depression.

Effects of dihydropyridine calcium channel blockers on oxidized low-density lipoprotein induced proliferation and oxidative stress of vascular smooth muscle cells

It is demonstrated that lipophilic CCBs, such as lacidipine may inhibit ox-LDL induced proliferation and oxidative stress of VSMCs, and that the ROS-MAPKs pathway might be involved in the mechanism.

Effects of labedipinedilol‐A, third‐generation dihydropyridine‐type calcium blocker, on ouabain‐induced arrhythmia

The results suggest that labedipinedilol‐A may reduce the membrane conduction through inhibition of ionic channels which decrease ouabain‐induced arrhythmia.



The Impact of Lacidipine, a Novel Dihydropyridine Calcium Antagonist, on Carbohydrate and Lipid Metabolism

It is concluded that lacidipine is a safe and effective drug in the long-term antihypertensive treatment of patients with essential hypertension and with concomitant metabolic disorders such as diabetes mellitus or dyslipidemia.

Effect of lacidipine on blood pressure, vasoactive hormones, and haemorheology in elderly patients with essential hypertension

Investigating the affects of lacidipine on the activity of the reninangiotensin-aldosterone system, plasma levels of natriuretic peptides and haemorheological profile in elderly patients with essential hypertension found it desirable that a calcium antagonist has a gradual onset and long duration of action and causes minimal activation of counterregulatory systems.

Efficacy and Safety of Lacidipine, a New Long‐Lasting Calcium Antagonist, in Elderly Hypertensive Patients

4 mg once daily is an effective and well-tolerated antihypertensive treatment in the elderly and, as with the general adult population, represents the optimal long-term maintenance dose.

Evaluation of lacidipine (a calcium blocker) in the treatment of hypertension in black African people: a double-blind comparison with hydrochlorothiazide.

The efficacy and tolerable of lacidipine (a calcium) blocker of the dihydropyridine class and hydrochlorothiazide (a diuretic) were compared in a 12 week double-blind randomised parallel group study of Nigerians with essential hypertension.

Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency.

It is suggested that renal function should be monitored closely in patients with renal insufficiency when a calcium antagonist is being used to control blood pressure, particularly in those with either marginal blood pressure control, significant albuminuria or an incipient nephrotic syndrome.

Pharmacology of Lacidipine, a Vascular‐Selective Calcium Antagonist

The marked vascular selectivity of lacidipine was clearly evident both in pithed rats infused with angiotensin II and in anesthetized dogs, in which preferential and long-lasting coronary and vertebral blood flow increases were also observed.

An assessment of lacidipine and atenolol in mild to moderate hypertension.

Assessment of the interaction between the new calcium antagonist, lacidipine and atenolol, in patients with mild to moderate hypertension found that exercise tolerance was not adversely affected and co-administration of both drugs produced a significant additive effect.

Clinical Pharmacology of Lacidipine

Two specialized electrophysiologic studies in patients confirmed that lacidipine does not affect pacemaker tissue and that it exhibits relative selectivity for the vascular smooth muscle, and its pharmacodynamic and pharmacokinetic profiles evaluated.

Safety aspects of treatment with lacidipine--a slow-onset, long-acting calcium antagonist.

Lidipine is found to be an effective and well tolerated drug with a reasonable adverse profile typical for a calcium antagonist of the dihydropyridine group, and a lower fatal event rate than previously reported in the actively treated hypertensives in Collins' meta-analyses.

A Long‐Term Study Comparing Lacidipine and Nifedipine SR in Hypertensive Patients: Safety Data

Lacidipine can be considered a safe antihypertensive drug, which can be used as a suitable agent for first‐line treatment of hypertension.